Back to Search Results
Alison EhrlichProfessor of Dermatology
Office Phone: 202-741-2627
- BA, Smith College, 1990
- MD, George Washington University, 1996
- M.H.S., NIH/Duke, 2002
Dr. Alison Ehrlich is board-certified in dermatology and is Professor and Chair of the Department of Dermatology at The George Washington University, Medical Faculty Associates. She is the Director of Clinical Research and oversees studies in the areas of psoriasis, contact dermatitis, atopic dermatitis, rosacea and dermatomyositis. Following her residency in Dermatology, she completed a fellowship in Clinical Research and Masters in Clinical Research through a combined NIH/Duke program. She specializes in the diagnosis and treatment of allergic contact dermatitis and psoriasis and autoimmune mediated disorders including dermatomyositis. She is sees patients in the Psoriasis clinic, Rheumatology/Dermatology joint clinic and the Patch test clinic. In addition, she oversees the dermatology cosmetic center within the Medical Faculty Associates. She is a past president of the DC Dermatological Society and past board member of the American Contact Dermatitis Society. She is a reviewer for JAAD, Archives of Dermatology, Dermatologic Surgery and Dermatitis. She is on The Scientific Advisory Board for the Asthma and Allergy Foundation. She has lectured both within the US and abroad on psoriasis and contact dermatitis and has published many papers on these topics. Dr. Ehrlich is a Washingtonian magazine “Top Doc” and a Washington Checkbook “Top Doc”.
Dr. Ehrlich's research interests include psoriasis, contact dermatitis, atopic dermatitis, rosacea and dermatomyositis.
View publications by this faculty member from January 1, 2013 - present
Additional publications published before January 1, 2013 may be available within Himmelfarb Library's database.
Industry Relationships and Collaborations
This faculty member (or a member of their immediate family) has reported a financial interest with the healthcare related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.
- Boehinger Ingleheim
- Janssen Pharmaceuticals
- Kiniksa Pharmaceuticals
- UCB Pharmaceuticals